News

Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...
Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?
Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 drugs ...
Eli Lilly Stock Drops as Lowered Profit Outlook Outweighs Solid Q1 Results
Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...
Eli Lilly CEO says tariffs are not the answer, urges Trump to move fast on trade deals
Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.
Bisnow3d
Eli Lilly Considers Houston For $5.9B Biomanufacturing Facility
Pharmaceutical manufacturing giant Eli Lilly and Co. is exploring potential economic incentives for a $5.9B biomanufacturing ...